Aug. 1 at 3:44 PM
$FLGT Note the acquisition:
"On July 9, 2025, the Company completed an acquisition of 100% of ANP, an innovation-driven company, which has developed multiple proprietary product platforms. The acquisition was structured as a combination of cash and stock, with a preliminary consideration of
$4.2 million, net of cash received. The consideration includes a contingent consideration of approximately
$5.7 million worth of the Company’s common stock based on ANP’s achievement of certain milestones as described in the acquisition agreement...
This acquisition enables the Company to secure ownership of the patents previously licensed from ANP, which are currently utilized in ongoing clinical studies. By securing full ownership of these intellectual property rights, the Company aims to enhance its control over the development and commercialization of related therapeutic candidates, thereby aligning with its strategic objectives to advance clinical programs."
